Scienture Holdings, Inc. - 8-K Filing

Scienture Holdings reports Q3 2026 revenue of $1.25 million, up 265% sequentially following REZENOPY™ commercial launch. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $MEDS

Read the full article at SEC EDGAR

More Regulatory news